Descriptive Evaluation of a Smoking Cessation Support Service for Chronic Disease Clients Within a Hospital Admissions Risk Program. (15th June 2015)

• Record Type: Journal Article
• Authors: Shields, Pam; Bradley, Robyn; Graco, Marnie; Hutchinson, A.
• Is Part Of: Journal of smoking cessation. Volume 12:Number 1(2017)
• Page Start: 22
• Page End: 31
• Publication Date: 2015-06-15
• Subjects: Smoking cessation -- Periodicals; Tobacco use -- Treatment -- Periodicals; Smoking -- Health aspects -- Periodicals; 616.86506
• DOI: 10.1017/jsc.2015.9
• Languages: English
• ISSNs: 1834-2612

Abstract

Abstract : Introduction: The Northern Alliance HARP smoking cessation program provides support to chronic disease participants who desired to quit smoking. This is an individualised program with pharmacotherapy and behavioural support, delivered by specialist clinicians. Aims: The aims of this descriptive evaluation were to explore factors that affect abstinence rates, record those rates, and describe the impact of anxiety, depression, self-efficacy, quality of life and motivation on quit rates at three months. Methods: Data was collected prospectively from clients enrolled in the service. Participants were assessed for abstinence at three months, six months and one year by carbon monoxide (CO) monitoring and self-reporting. Factors predictive of quitting were analysed using logistic regression; factors with a p value < 0.05 and 95% CI not containing one were considered statistically significant. Results: 103 clients were assessed and 86 were enrolled in the program. The odds of successful quitting at three months CO verified was higher amongst completers of the program compared to non-completers (OR = 6.6, 95% CI = 2.03–21.57, p = 0.002). The probability of sustained quitting at one year was over 18 times higher in the group who completed the program ( n = 16/21 completers and n = 1/4 non-completers) (OR 18.5, 95% CI, 2.32–147.34, p = 0.006). No other factors predicted quitting. The rate of quitting was 28.7% at three months, 19.5% at six months and 10.3% at one year, CO verified. Measures of anxiety and depression, self-efficacy, quality of life and motivation did not influence either the quit rate or the likelihood of completing the course of treatment at three months.